Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06783621 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products
A Phase 4 study of Facial Contouring, sponsored by AbbVie.
- Active
- Registry status
- Phase 4
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT06783621: Active Phase 4 study of Facial Contouring, sponsored by AbbVie.
NCT06783621 is a Phase 4 study of Facial Contouring that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 130 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06783621, a Phase 4 study of Facial Contouring, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA, CoolSculpting Elite, and select SkinMedica products in a diverse population.
Primary Outcome
The FACE-Q Satisfaction with Facial Appearance is a validated questionnaire that asks participants to report their level of satisfaction with the appearance of their face.
Conditions Studied
Interventions
- DRUG OnabotulinumtoxinA
- DEVICE CoolSculpting Elite System
- DEVICE JUVÉDERM
- OTHER SkinMedica Products
- DRUG KYBELLA
Study Locations (10)
California
- Marcus Facial Plastic Surgery /ID# 270408 - Redondo Beach
- Pacific Clinical Innovations /ID# 270414 - Vista
Texas
- Bellaire Dermatology Associates /ID# 270429 - Bellaire
- Integrated Aesthetics /ID# 270399 - Spring
District of Columbia
- Center for Dermatology and Dermatologic Surgery /ID# 270390 - Washington D.C.
Florida
- Skin Research Institute LLC /ID# 270410 - Coral Gables
Louisiana
- DelRicht Research - New Orleans 308 /ID# 270425 - New Orleans
Michigan
- Boyd /Id# 270509 - Birmingham
New York
- Luxurgery /ID# 270430 - New York
Virginia
- SkinDC /ID# 270411 - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-01-16 |
| Est. Completion | 2026-03 |
| Phase | Phase 4 |
What the registry record for NCT06783621 still lists
NCT06783621 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Facial Contouring appearing as the primary indexed condition, and to 5 interventions - of which OnabotulinumtoxinA is the first listed.
NCT06783621 lists 10 locations in 8 states (California, Texas, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT06783621 about?
NCT06783621 is a clinical study titled "A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products". A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA, CoolSculpting Elite, and select SkinMedica products in a diverse population.
What is the current status of trial NCT06783621?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2025-01-16. Estimated completion is 2026-03.
What conditions does trial NCT06783621 study?
This clinical trial studies the following conditions: Facial Contouring.
What interventions are being tested in trial NCT06783621?
The interventions under investigation include: OnabotulinumtoxinA (DRUG), CoolSculpting Elite System (DEVICE), JUVÉDERM (DEVICE), SkinMedica Products (OTHER), KYBELLA (DRUG).
Who is sponsoring clinical trial NCT06783621?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06783621 being conducted?
This trial has 10 study locations across California, District of Columbia, Florida, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06783621's enrollment target sits among peer trials
130 622nd of 2000 higher than 1,371 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI